Data compiled by Redley Lamar · ChainSifter Intelligence
2Suppliers
5Customers
3Debt Items
17Related Chains
Source-Backed Evidence Depth
Protara Therapeutics, Inc. (TARA) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
11Total relationships
1Distinct source URLs
5High confidence
0.765Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Protara Therapeutics, Inc. Suppliers
Ticker
Name
Confidence
Evidence
THE-FEINSTEIN-INSTITUTE-FOR-MEDICAL-RESEARCH
THE-FEINSTEIN-INSTITUTE-FOR-MEDICAL-RESEARCH
90%
As consideration for the license grant, we agreed to pay the Institute tiered royalties of between 1.0% and 1.5% of all net sales.
Reciprocal relationship from PVLA graph: ion, future events, or otherwise, except as may be required by law. SUMMARY OF PRINCIPAL RISK FACTORS Below is a summary of material factors that make an inve…
Reciprocal relationship from BDRX graph: l lawsuits challenging state authority to regulate prescription drug payment limits. Furthermore, in December 2020, the U.S. Supreme Court held unanimously th…
ARTARA-SUBSIDIARY-INC
ARTARA-SUBSIDIARY-INC
62%
e or fraudulent claim for purposes of the federal False Claims Act, or the FCA. 32 The federal false claims, including the FCA, and civil monetary penalty laws, which imposes significant penalties an…
ARTARA-THERAPEUTICS-INC
ARTARA-THERAPEUTICS-INC
62%
e or fraudulent claim for purposes of the federal False Claims Act, or the FCA. 32 The federal false claims, including the FCA, and civil monetary penalty laws, which imposes significant penalties an…
PROTEON-THERAPEUTICS-INC
PROTEON-THERAPEUTICS-INC
62%
e or fraudulent claim for purposes of the federal False Claims Act, or the FCA. 32 The federal false claims, including the FCA, and civil monetary penalty laws, which imposes significant penalties an…
PROTEON-THERAPEUTICS-LLC
PROTEON-THERAPEUTICS-LLC
62%
e or fraudulent claim for purposes of the federal False Claims Act, or the FCA. 32 The federal false claims, including the FCA, and civil monetary penalty laws, which imposes significant penalties an…
Protara Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
TARA-DEBT
Debt stack $3.1M
90%
Market cache reports total debt of $3.1M.
TARA-DEBT-12880
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2019-09-23.
TARA-DEBT-12879
Warrants outstanding: 1700000
90%
xbrl warrant detail from xbrl 2024-12-31.
Protara Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Protara Therapeutics, Inc..
Protara Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
TARA-OWNER-JANUS-HENDERSON-GROUP-PLC
JANUS HENDERSON GROUP PLC
90%
13F overlay lists JANUS HENDERSON GROUP PLC as top holder; 114 tracked holders.
Protara Therapeutics, Inc. Extended Supply Chain Network
